ST. PETERSBURG, FLORIDA | Cognitive Research Corporation (CRC), a leading neuroscience clinical services company, announced that C. Gordon “Chip” Gillooly has been named Chief Executive Officer. Mr. Gillooly succeeds Dr. Tom Hochadel, Co-Founder, who will now serve as President and will continue to play an integral role in the company’s growth and delivery of exceptional CRO services to our clients. Dr. Gary Kay, Co-Founder and Head of Psychometric Assessments, will remain Chief Science Officer. CRC has been supporting clinical development for CNS-focused small to mid-size pharma, biotech, and medical device companies for over 16 years. The company has experienced explosive growth over the past five years as the CNS market has accelerated.

“CRC has a tremendous track record of providing innovative companies scientific and clinical research services to the highest level of ethical standards and performance,” said Dr. Hochadel. Our ability to partner with our clients and provide a full spectrum of CRO services as well as Psychometric Assessment Technologies has positioned us well for the future. With Chip now at the company’s helm we are poised to build on our momentum and take the company to the next level. I see a great future for our company as we continue to expand our leadership team and clinical capabilities to meet the increasingly complex needs of our clients.”

“It is truly a privilege to join this exceptional team of professionals and I am grateful for Tom and Gary’s confidence in me, said Gillooly. I am very excited to begin working closely with my CRC colleagues as we continue to provide bespoke clinical services to emerging life science companies across the globe. Our consistent growth and the longevity of our client partnerships underscores the value and attentiveness we bring to our clients. This team loves to work with clients and to make a difference in patient’s lives.”

Gillooly previously served as CEO of a Medtech startup focused on addressing the growing challenge of Hospital Acquired Infections. Prior to that, he was a Global Vice President at Quintiles (now IQVIA) focused on investing and providing clinical development services to emerging companies worldwide. He has spent more than two decades in the life science and medical technology space partnering with leading scientific companies and their investors to advance drug development and supporting technologies.

About Cognitive Research Corporation:
CRC’s mission is to support innovative companies developing new medicines and therapies to improve mental health. As a leading neuroscience clinical research organization (CRO) and technology company, CRC works with sponsors, specialized clinical trial sites, and CNS experts to bring new drugs through rigorous testing and ultimately to market. For more information visit: http://www.cogres.com